JP2022502434A5 - - Google Patents
Info
- Publication number
- JP2022502434A5 JP2022502434A5 JP2021517299A JP2021517299A JP2022502434A5 JP 2022502434 A5 JP2022502434 A5 JP 2022502434A5 JP 2021517299 A JP2021517299 A JP 2021517299A JP 2021517299 A JP2021517299 A JP 2021517299A JP 2022502434 A5 JP2022502434 A5 JP 2022502434A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- weeks
- sfrp2
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737155P | 2018-09-27 | 2018-09-27 | |
| US62/737,155 | 2018-09-27 | ||
| PCT/US2019/053651 WO2020069439A1 (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502434A JP2022502434A (ja) | 2022-01-11 |
| JP2022502434A5 true JP2022502434A5 (cg-RX-API-DMAC10.html) | 2022-10-05 |
| JP7451506B2 JP7451506B2 (ja) | 2024-03-18 |
Family
ID=69953118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517299A Active JP7451506B2 (ja) | 2018-09-27 | 2019-09-27 | がんの治療用の薬学的組合せ |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021013222A (es) * | 2019-05-03 | 2022-01-06 | Genentech Inc | Metodos para tratar el cancer con un anticuerpo anti-pd-l1. |
| WO2025199292A1 (en) * | 2024-03-21 | 2025-09-25 | Musc Foundation For Research Development | A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2285989B1 (en) | 2008-05-15 | 2016-11-16 | The University of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| WO2011119524A1 (en) | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| WO2014022774A1 (en) | 2012-08-02 | 2014-02-06 | Fred Hutchinson Cancer Research Center | Treatment induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins |
| EP3313441B1 (en) * | 2015-06-24 | 2024-02-21 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| HK1254404A1 (zh) * | 2015-06-25 | 2019-07-19 | Advanced Accelerator Applications | 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| PL3964529T3 (pl) * | 2016-01-22 | 2025-10-27 | MabQuest SA | Nieblokujące przeciwciała specyficzne względem pd1 |
| CN110267682A (zh) * | 2017-02-14 | 2019-09-20 | 诺华股份有限公司 | Wnt抑制剂和抗PD-1抗体分子组合的给药方案 |
-
2019
- 2019-09-27 BR BR112021005525-8A patent/BR112021005525A2/pt unknown
- 2019-09-27 MX MX2021003274A patent/MX2021003274A/es unknown
- 2019-09-27 AU AU2019351267A patent/AU2019351267B2/en active Active
- 2019-09-27 US US17/279,857 patent/US20210395351A1/en active Pending
- 2019-09-27 SG SG11202102865WA patent/SG11202102865WA/en unknown
- 2019-09-27 JP JP2021517299A patent/JP7451506B2/ja active Active
- 2019-09-27 CN CN202411827485.1A patent/CN119818670A/zh active Pending
- 2019-09-27 KR KR1020217012004A patent/KR102947706B1/ko active Active
- 2019-09-27 CA CA3114173A patent/CA3114173A1/en active Pending
- 2019-09-27 CN CN201980076608.3A patent/CN113454114B/zh active Active
- 2019-09-27 EP EP19866195.1A patent/EP3856784A4/en active Pending
- 2019-09-27 WO PCT/US2019/053651 patent/WO2020069439A1/en not_active Ceased
-
2021
- 2021-03-24 IL IL281782A patent/IL281782A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69932600T2 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
| Lewis Phillips et al. | Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis | |
| US20020076408A1 (en) | Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody | |
| JP2022513685A5 (cg-RX-API-DMAC10.html) | ||
| JP2003520195A (ja) | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 | |
| CN109153724A (zh) | 通过施用pd-1抑制剂治疗皮肤癌的方法 | |
| MXPA02011194A (es) | Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales. | |
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2012136535A (ja) | 癌治療のためのrhuMAbHER2と組み合わせたドセタキセル | |
| AU2018101488A4 (en) | Method and kit for treating cancer through combination therapy | |
| WO2021182573A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
| JP2025060639A (ja) | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| DE60316106T2 (de) | Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung | |
| CN109476733A (zh) | 使用il-17拮抗剂治疗新发斑块型银屑病的方法 | |
| DE69837322T2 (de) | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln | |
| WO2021182572A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
| CN113318226A (zh) | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 | |
| JP2023537115A5 (cg-RX-API-DMAC10.html) | ||
| KR20240168479A (ko) | 건선 치료 방법 | |
| EP4115902A1 (en) | Combined use of ctb006 and ponatinib | |
| CN118076377A (zh) | 人类表皮生长因子第二型受体疫苗组成物 | |
| Gaustad et al. | Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression | |
| Zhang et al. | A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer | |
| EP3976037A1 (en) | Compositions and methods to treat cancer | |
| KR102834430B1 (ko) | 전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물 |